Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by JPMorgan Chase & Co. from $455.00 to $457.00 in a research note issued to investors on Wednesday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 22.08% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. BTIG Research reiterated a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Piper Jaffray Companies reiterated a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, SunTrust Banks reiterated a “hold” rating and set a $435.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 2nd. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $471.19.
Regeneron Pharmaceuticals (REGN) traded down $17.48 during trading hours on Wednesday, reaching $374.36. 1,414,838 shares of the company’s stock traded hands, compared to its average volume of 681,361. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a 52-week low of $340.96 and a 52-week high of $543.55. The stock has a market cap of $38,430.00, a P/E ratio of 34.00, a P/E/G ratio of 1.50 and a beta of 1.52.
Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $130,000. Steward Partners Investment Advisory LLC boosted its position in shares of Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 307 shares during the last quarter. Vident Investment Advisory LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $200,000. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $206,000. Finally, Moors & Cabot Inc. acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $217,000. 66.82% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
